- Home
- DMAC vs BWFG Comparison
DMAC vs BWFG Comparison
Compare DMAC & BWFG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- BWFG
- Stock Information
- Founded
- DMAC 2000
- BWFG 2002
- Country
- DMAC United States
- BWFG United States
- Employees
- DMAC N/A
- BWFG N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- BWFG Major Banks
- Sector
- DMAC Health Care
- BWFG Finance
- Exchange
- DMAC Nasdaq
- BWFG Nasdaq
- Market Cap
- DMAC 310.1M
- BWFG 333.1M
- IPO Year
- DMAC N/A
- BWFG N/A
- Fundamental
- Price
- DMAC $6.97
- BWFG $44.37
- Analyst Decision
- DMAC Strong Buy
- BWFG Buy
- Analyst Count
- DMAC 3
- BWFG 2
- Target Price
- DMAC $12.33
- BWFG $42.00
- AVG Volume (30 Days)
- DMAC 443.2K
- BWFG 40.7K
- Earning Date
- DMAC 11-12-2025
- BWFG 10-27-2025
- Dividend Yield
- DMAC N/A
- BWFG 1.80%
- EPS Growth
- DMAC N/A
- BWFG N/A
- EPS
- DMAC N/A
- BWFG 2.64
- Revenue
- DMAC N/A
- BWFG $81,749,000.00
- Revenue This Year
- DMAC N/A
- BWFG $66.56
- Revenue Next Year
- DMAC N/A
- BWFG $14.45
- P/E Ratio
- DMAC N/A
- BWFG $16.83
- Revenue Growth
- DMAC N/A
- BWFG 0.32
- 52 Week Low
- DMAC $3.19
- BWFG $26.39
- 52 Week High
- DMAC $7.49
- BWFG $46.63
- Technical
- Relative Strength Index (RSI)
- DMAC 66.23
- BWFG 65.13
- Support Level
- DMAC $6.83
- BWFG $41.55
- Resistance Level
- DMAC $7.41
- BWFG $46.63
- Average True Range (ATR)
- DMAC 0.42
- BWFG 0.98
- MACD
- DMAC 0.06
- BWFG 0.11
- Stochastic Oscillator
- DMAC 77.88
- BWFG 55.41
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About BWFG Bankwell Financial Group Inc.
Bankwell Financial Group Inc is a bank holding company, engaged in providing financial products and services. It offers products related to commercial lending, retail lending, depository services, and others. The bank's commercial lending products includes owner-occupied commercial real estate loans, commercial real estate investment loans, commercial loans to small and mid-sized businesses and real estate construction and development loans. The retail lending products include residential mortgage loans, home equity lines of credit, and consumer installment loans. Its depository products include checking, savings, money market, certificates of deposit, noninterest-bearing demand, and time deposits.